Haite Biotech announced that its subsidiary Wuhan Haite Biotech Innovative Pharmaceutical Research Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for HKG-320 injections approved and issued by the State Drug Administration.
海特生物：子公司获得药物临床试验批准通知书
Haite Biotech: Subsidiary Receives Drug Clinical Trial Approval Notice
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.